Initial Public Offering
Baird served as a co-manager on this offering.
AboutNanoString Technologies, Inc. (“NanoString” or the “Company”) (NASDAQ: NSTG) recently completed an initial public offering of 5,400,000 shares of common stock at a price of $10.00 per share, generating gross proceeds of $54 million. The Company intends to use the net proceeds from the offering to commercialize Prosigna after obtaining regulatory authorization, including establishing a dedicated oncology sales force, to expand the clinical utility of Prosigna and to develop other potential diagnostic product opportunities, to expand life sciences commercial operations to grow and support the installed base of the nCounter Analysis Systems among life sciences research customers in the United States and internationally and for working capital and general corporate purposes.
NanoString develops, manufactures and sells robust, intuitive products that unlock scientifically valuable and clinically actionable genomic information from minute amounts of tissue. The Company’s nCounter Analysis System directly profiles hundreds of molecules simultaneously using a novel barcoding technology. NanoString markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of disease. The Company is also seeking FDA clearance for its first molecular diagnostic product, the Prosigna Breast Cancer Assay, to assess a patient’s risk of recurrence for breast cancer. In February 2013, the Company commercially launched Prosigna in Europe and Israel. NanoString is based in Seattle, Washington.
For additional information about this transaction, please contact:
- June 2013
- NanoString Technologies, Inc.
- Target Location
- North America